Product Information
EQUETRO 200 MG CAPSULE is a brand product labeled by Validus Pharmaceuticals LLC, priced at $4.1842 per EA under NDC 30698042112. Its NADAC has been published 306 times since Nov 28, 2013.
FDA first approved this application on Dec 10, 2004.
The High Outlier badge above means this manufacturer's average price in the Carbamazepine market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
200 mg/1
Manufacturer
Validus Pharmaceuticals LLCNDC
30698042112
Classification
Brand
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CARBAMAZEPINEApproval Type
New Drug (NDA)
FDA Application
NDA021710FDA Approved
12/10/2004
On Market Since
12/10/2004
Pharmacological Classes
Price Statistics
The NADAC for EQUETRO 200 MG CAPSULE has been published 306 times since Nov 28, 2013, and over the history we have for it it has risen 99.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $4.1842 per EA |
|---|---|
| All-time high | $4.1842 (Sep 30, 2026) |
| All-time low | $2.1027 (Nov 28, 2013) |
| 52-week high | $4.1842 |
| 52-week low | $4.1573 |
| Median price | $4.1637 |
| Average price | $3.6208 |
| Largest weekly change | +38.6% (May 21, 2014) |
| Weeks tracked | 306 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 75% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Validus Pharmaceuticals LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Carbamazepine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Mood Stabilizer class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of EQUETRO 200 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for EQUETRO 200 MG CAPSULE, manufactured by Validus Pharmaceuticals LLC, is $4.1842 per EA (NDC 30698042112), effective Sep 30, 2026.
How has the price of EQUETRO 200 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for EQUETRO 200 MG CAPSULE has risen 99.0%. It has been tracked across 306 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for EQUETRO 200 MG CAPSULE?
Since Nov 28, 2013, the NADAC for EQUETRO 200 MG CAPSULE has ranged from a low of $2.1027 (Nov 28, 2013) to a high of $4.1842 (Sep 30, 2026), with a median of $4.1637 per EA.
Are there cheaper alternatives to EQUETRO 200 MG CAPSULE?
Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, CARBAMAZEPINE ER 200 MG CAP, is $1.0527 per EA — about 75% below EQUETRO 200 MG CAPSULE.
Who manufactures EQUETRO 200 MG CAPSULE?
EQUETRO 200 MG CAPSULE (NDC 30698042112) is labeled by Validus Pharmaceuticals LLC, and CMS classifies it as a brand product.